Skip to content

KA-PHARMA

Active
Private limited companyfounded 20242 yrs activeJoseph Baecklaan 74, 1080 Sint-Jans-Molenbeek, BelgiumKBO/BCE: BE 1005.869.016
Summary

The computed 12-month bankruptcy probability of KA-PHARMA is 1.5% (moderate). The 2024 annual accounts show equity of €109k and a net result of €106k. Its solvency ranks better than 93% of 9517 sector peers (fiscal year 2024). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.

Checked score

Score 2024
Axes
Profitability100
Solvency100
Growth-
Track record67
Bankruptcy probability, 12 months
1.5% Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €8k at 30 days only on tighter terms
Liquidity ample (current ratio 13.68; short-term debt: 7.2% and cash: 18.7% of total assets), and 7.2% of the assets are financed with debt.
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 y
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 82
Relative position
BE, all sectors
reference
Office administrative, office support and other business support activities (NACE 82)
about 37% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024
Solvency, return and age of the figures
Solvency
92.8%
Return on assets
90.2%
Age of the figures
21 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 31-08-2025, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 1 filing
Deviation from the deadline
2024
31 d late
← before the deadline after the deadline →
Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 9 February 2024, KA-PHARMA was incorporated as a Private limited company.1 The company has filed annual accounts once, for fiscal year 2024.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2024

Go further with this company

Is this your company? See how customers and banks see it.

Financials · fiscal year 2024, micro schema

Source amounts without an identifiable currency are assumed to be EUR.

Equity
€109k
Total assets
€117k
Net result
€106k
Working capital
€108k

Turnover and EBIT margin not published: the micro schema does not require them.

Balance-sheet composition
Assets €117k
Fixed assets €1k
Current assets €116k
Equity and liabilities €117k
Equity €109k
Debt €9k
Debt finances 7.2% of the balance-sheet total.
Key figures and ratios
2024 value
EBITDA
€106k
Cash flow
€106k
Current ratio
13.68
Debt to equity
0.08
ROE
97.2%
ROA
90.2%
Debt ≤ 1 year
€9k
Staff costs
€76
Annual accounts
Filed annual accounts As filed with the NBB · 2024 · 28 lines
Balance sheet Code2024
Assets
Total assets20/58€117k
Fixed assets21/28€1k
Tangible fixed assets22/27€1k
Furniture and vehicles24€1k
Current assets29/58€116k
Amounts receivable within one year40/41€94k
Trade receivables40€16k
Other amounts receivable41€79k
Cash at bank and in hand54/58€22k
Equity and liabilities
Total equity and liabilities10/49€117k
Equity10/15€109k
Contributions10/11€3k
Profit (loss) carried forward14€106k
Amounts payable17/49€9k
Amounts payable within one year42/48€9k
Trade debts44€2k
Suppliers440/4€2k
Taxes, remuneration and social security45€7k
Taxes450/3€7k
Income statement Code2024
Remuneration, social security and pensions62€76
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€336
Other operating charges640/8€321
Gross operating margin9900€107k
Operating profit (loss)9901€106k
Profit (loss) for the period before taxes9903€106k
Profit (loss) for the period9904€106k
Profit (loss) for the period to be appropriated9905€106k
Appropriation of the result
Profit (loss) to be appropriated9906€106k

The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2024
Remuneration, social security and pensions62€76
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€336
Other operating charges640/8€321
Gross operating margin9900€107k
Operating profit (loss)9901€106k
Profit (loss) for the period before taxes9903€106k
Profit (loss) for the period9904€106k
Profit (loss) for the period to be appropriated9905€106k
Line2024
Assets
Total assets20/58€117k
Fixed assets21/28€1k
Tangible fixed assets22/27€1k
Furniture and vehicles24€1k
Current assets29/58€116k
Amounts receivable within one year40/41€94k
Trade receivables40€16k
Other amounts receivable41€79k
Cash at bank and in hand54/58€22k
Equity and liabilities
Total equity and liabilities10/49€117k
Equity10/15€109k
Contributions10/11€3k
Profit (loss) carried forward14€106k
Amounts payable17/49€9k
Amounts payable within one year42/48€9k
Trade debts44€2k
Suppliers440/4€2k
Taxes, remuneration and social security45€7k
Taxes450/3€7k
Line2024
Profit (loss) for the period9904€106k
+ Depreciation and write-downs630€336
Operating cash flow (approximation)€106k

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2025
31-08
NBB filing Annual accounts filed
fiscal year 2024 · micro schema · 31 days late
NBB filing
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Sint-Jans-Molenbeek · 1 establishment unit since 2024
seat establishment The establishment unit on the map
Ground area
7,479 m²
Building footprint
280 m²
Volume, LiDAR
9,684 m³
Parcel 21523B0861/00D000, Brussels · tallest building 37.2 m, ±12 floors. Linked by address, not a title deed.
16 companies at this address See who is registered here
1 establishment unit
KA-PHARMA
Joseph Baecklaan 74, 1080 Sint-Jans-MolenbeekOther business support services
since 20242.355.572.546
1 parcel
Brussels 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
21523B0861/00D000 Brussels 7,479 m² 1 · 280 m² 37.2 m · 12 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Similar companies · same sector, comparable size

Of 24,515 companies in sector 82990 we hold annual accounts for 9,413. 7,185 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded09-02-2024
Fiscal year end31-12
Activities, NACEBEL 2025
82990Other business support services

Scores and ratios are computed by Checked and are not a credit decision.